AbbVie Inc. — SKYRIZI (risankizumab-rzaa) · Pediatric plaque psoriasis / active psoriatic arth.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/9/26) through T+5. Run-up high $243.14 on 6/25/26, low $197.38 on 4/29/26 (T-120 to T-1). FDA decision 6/26/26. Historical price action, not a forecast.